Oppenheimer Thinks uniQure NV’s Stock is Going to Recover

By Austin Angelo

Oppenheimer analyst Hartaj Singh reiterated a Buy rating on uniQure NV (NASDAQ: QURE) today and set a price target of $17. The company’s shares opened today at $5.09, close to its 52-week low of $4.72.

Singh commented:

“UniQure (QURE) provided an earnings and business update on May 9, followed by an update on the preclinical Huntington’s program AMT-130 (among other abstracts) at the American Society for Gene & Cell Therapy meeting in Washington, D.C. on May 12. While refreshing to see another product headed into the clinic (Huntington’s in 2018), investors are currently focused on the planned pivotal Phase 3 trial—expected to initiate in 2018—of AMT-060 in patients with severe hemophilia B. We are also excited to see up to 18 months of follow-up AMT-060 data from the ongoing Phase 1/2 study at the ISTH meeting in early July, as long-term safety is a key differentiator for AMT-060.”

According to TipRanks.com, Singh is a 1-star analyst with an average return of -1.5% and a 43.5% success rate. Singh covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Alexion Pharmaceuticals.

uniQure NV has an analyst consensus of Moderate Buy, with a price target consensus of $12.50.

Based on uniQure NV’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.54 million and GAAP net loss of $21.61 million. In comparison, last year the company earned revenue of $4.3 million and had a GAAP net loss of $22.69 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, Netherlands.